<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00982722</url>
  </required_header>
  <id_info>
    <org_study_id>Eudra CT 2007-003691-19</org_study_id>
    <nct_id>NCT00982722</nct_id>
  </id_info>
  <brief_title>Vitamin D Supplementation After Parathyroid Surgery</brief_title>
  <official_title>Vitamin D Supplementation After Successful Parathyroid Surgery for Primary Hyperparathyroidism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomised double blind clinical trial, accepted by the Medical Products Agency and
      registered in the European Clinical Trials Database. Aims to evaluate the prevalence of
      vitamin D deficiency in a pHPT population in relation to gender and age, the correlation
      between vitamin D status, pre- and postoperative parathyroid hormone level and bone density
      and the correlation between vitamin D status, metabolic, cardiovascular risk factors and QoL
      aspects before and after parathyroid adenomectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      150 PHPT patients were randomized six weeks after surgery, 75 into each group, to 1 year of
      oral treatment with either calcium carbonate 1 g (500 mg twice daily) alone or calcium
      carbonate 1 g combined with cholecalciferol 1600 IU (800 IU twice daily). Exclusion criteria
      were age under 18, manifest osteoporosis at PHPTdiagnosis, persistent hypercalcemia after
      surgery, postoperative hypocalcemia requiring vitamin D treatment, glomerular filtration rate
      (GFR) below 40 ml/min, pregnancy, breast feeding, or logistical difficulties, for example
      living far from the hospital. Included patients had to withdraw any current supplementation
      with calcium and vitamin D during the study period. All tablets were identical in appearance,
      the tins were numbered and randomization followed a list compiled by an independent clinical
      research support organization. The time for randomization was chosen to make sure that the
      PHPT patients were cured before starting the study medication. Nearly three-quarters of the
      patients were randomized within 6 weeks after PTX.The primary end point was the change in PTH
      after PTX and treatment with the study medication. Secondary end points were vitamin D
      levels, insulin resistance, blood pressure and other cardiovascular risk factors, biochemical
      markers of bone turnover, bone mineral density and self estimated health related quality of
      life (SF- 36).
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>postoperative parathyroid hormone level</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>bone mineral density</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ambulatory blood pressure</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>25-OH Vitamin D</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calcium</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Primary Hyperparathyroidism</condition>
  <arm_group>
    <arm_group_label>cholecalciferol and calcium carbonate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cholecalciferol 800 IUx2 and calcium carbonate 500 mg x 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>calciumcarbonate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>calcium carbonate 500 mg x 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cholecalciferol and calcium carbonate</intervention_name>
    <description>cholecalciferol 800 IUx2 and calcium carbonate 500 mg x 2 one year after parathyroid adenomectomy, initiated 6 weeks after surgery</description>
    <arm_group_label>calciumcarbonate</arm_group_label>
    <other_name>calcium carbonate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>calcium carbonate</intervention_name>
    <description>calcium carbonate 500 mg x 2 one year after parathyroid adenomectomy, initiated 6 weeks after surgery</description>
    <arm_group_label>cholecalciferol and calcium carbonate</arm_group_label>
    <other_name>cholecalciferol and calcium carbonate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary hyperparathyroidism subjected to parathyroid surgery

        Exclusion Criteria:

          -  Renal insufficiency

          -  Severe osteoporosis

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Inga-Lena Nilsson, MD, Ass prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska UH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Karolinska UH</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <results_reference>
    <citation>Norenstedt S, Pernow Y, Zedenius J, Nordenström J, Sääf M, Granath F, Nilsson IL. Vitamin D supplementation after parathyroidectomy: effect on bone mineral density-a randomized double-blind study. J Bone Miner Res. 2014 Apr;29(4):960-7. doi: 10.1002/jbmr.2102.</citation>
    <PMID>24115138</PMID>
  </results_reference>
  <results_reference>
    <citation>Norenstedt S, Pernow Y, Brismar K, Sääf M, Ekip A, Granath F, Zedenius J, Nilsson IL. Primary hyperparathyroidism and metabolic risk factors, impact of parathyroidectomy and vitamin D supplementation, and results of a randomized double-blind study. Eur J Endocrinol. 2013 Oct 21;169(6):795-804. doi: 10.1530/EJE-13-0547. Print 2013 Dec.</citation>
    <PMID>24026893</PMID>
  </results_reference>
  <results_reference>
    <citation>Åberg V, Norenstedt S, Zedenius J, Sääf M, Nordenström J, Pernow Y, Nilsson IL. Health-related quality of life after successful surgery for primary hyperparathyroidism: no additive effect from vitamin D supplementation: results of a double-blind randomized study. Eur J Endocrinol. 2015 Feb;172(2):181-7. doi: 10.1530/EJE-14-0757. Epub 2014 Nov 20.</citation>
    <PMID>25414430</PMID>
  </results_reference>
  <results_reference>
    <citation>Nilsson IL, Norenstedt S, Granath F, Zedenius J, Pernow Y, Larsson TE. FGF23, metabolic risk factors, and blood pressure in patients with primary hyperparathyroidism undergoing parathyroid adenomectomy. Surgery. 2016 Jan;159(1):211-7. doi: 10.1016/j.surg.2015.06.057. Epub 2015 Oct 2.</citation>
    <PMID>26435425</PMID>
  </results_reference>
  <results_reference>
    <citation>Nilsson IL, Norenstedt S, Zedenius J, Pernow Y, Bränström R. Primary hyperparathyroidism, hypercalciuria, and bone recovery after parathyroidectomy. Surgery. 2017 Aug;162(2):429-436. doi: 10.1016/j.surg.2017.02.017. Epub 2017 May 15.</citation>
    <PMID>28522130</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2009</study_first_submitted>
  <study_first_submitted_qc>September 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2009</study_first_posted>
  <last_update_submitted>May 26, 2017</last_update_submitted>
  <last_update_submitted_qc>May 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska University Hospital</investigator_affiliation>
    <investigator_full_name>Inga-Lena Nilsson</investigator_full_name>
    <investigator_title>Assoc prof, senior consultant</investigator_title>
  </responsible_party>
  <keyword>primary hyperparathyroidism</keyword>
  <keyword>postoperative vitamin D supplementation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism, Primary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Calcium Carbonate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

